Chronological age tells us only how much time has passed since birth. Yet two people of the same age may have very different cardiovascular health, metabolism, immunity and physical capacity. Biological age tests aim to make this difference measurable.
Today, epigenetic clocks based on DNA methylation are among the most powerful and best-researched tools available for assessing the biology of ageing. But the right question is not simply “What is my biological age?” What a particular test measures, how reproducible its result is and how it is interpreted alongside clinical information matter much more.
In brief:
What you need to know about biological age tests
There is no single, universal gold standard for biological age. Different tests measure different layers of ageing.
Epigenetic clocks examine methylation patterns on DNA, not the DNA sequence itself. This is currently one of the strongest areas of biological ageing research.
OMICmAge, DunedinPACE and SYMPHONYAge do not answer the same question. One concerns overall biological age and health risk, another the pace of ageing, and the third system-specific patterns of ageing.
A single result does not provide a diagnosis or predict lifespan with certainty. The most meaningful interpretation considers medical history, examination, laboratory results, body composition and physical capacity together.
One of the most valuable uses of these tests is monitoring change over time. This requires comparison using the same method and, where possible, the same laboratory.
How Is Biological Age Measured, and How Reliable Are Biological Age Tests?
What is biological age?
Biological age is a concept that attempts to describe how much the body has deteriorated, or how well it has maintained its functional capacity, relative to chronological age.
For example, a 50-year-old person may have better blood pressure, glucose metabolism, muscle strength, aerobic capacity and kidney function than most of their peers. Another 50-year-old may show a faster pattern of biological ageing because of smoking, inactivity, sleep disorders, visceral fat accumulation or chronic disease.
The critical point is this: there is no single “true age” written on the body as a whole. Cellular, molecular, metabolic and functional ageing are interconnected, but they are not exactly the same thing. Biological age should therefore be viewed as a multidimensional health profile rather than just one number.
How is biological age measured?
Biological age can be calculated from different types of data:
Clinical biomarkers: Composite scores derived from routine data such as blood glucose, HbA1c, CRP, albumin, creatinine, blood cell counts and blood pressure.
Epigenetic clocks: Age, pace of ageing or system ages calculated from DNA methylation patterns in blood.
Proteomic and metabolomic measurements: Assessment of patterns of proteins and metabolites in the blood.
Imaging-based measurements: Age estimates calculated from brain MRI, vascular imaging or images of different organs.
Functional measurements: Indicators directly related to everyday capacity, such as VO₂max, grip strength, walking speed, balance and body composition.
Telomere measurements: Assessment of the length of telomeres at the ends of chromosomes, either directly or through estimates based on DNA methylation.
None of these methods captures ageing in its entirety on its own. A good longevity assessment considers molecular data, conventional medical risk indicators and real-world function together.
What is an epigenetic clock, and how does it work?
Epigenetic clocks do not look for genetic mutations that change the letters of the DNA sequence. Instead, they measure methylation marks at specific sites on DNA. These marks can change with age, lifestyle, environmental exposures, cell type and disease processes.
Researchers develop mathematical models by selecting particular patterns from hundreds of thousands of methylation sites. But not all clocks are trained towards the same target:
First-generation clocks mostly aim to predict chronological age.
Newer clocks aim to capture features associated with disease burden, organ function, healthspan or mortality risk.
“Pace of ageing” tests estimate the current rate of ageing rather than the age a person has reached.
System clocks aim to show how ageing is distributed across areas such as the heart, metabolism or immunity.
A test’s ability to estimate chronological age within a few years does not necessarily make it the most clinically valuable test. What matters more is how the measurement relates to future health outcomes and whether it can reveal meaningful change during follow-up.
Which biological age test is the most reliable?
There is currently no single biological age test that applies to everyone, covers every organ and is universally accepted as “the most reliable”. Nevertheless, newer DNA methylation-based epigenetic measurements are well positioned because they have been tested in large human cohorts and show associations with multiple health outcomes.
Rather than asking for the “best test”, it is more appropriate to ask “Which test best fits the clinical question?”:
The question being asked | A more suitable measurement |
|---|---|
What is my overall pattern of ageing and health risk? | Biological age measurements developed around health outcomes, such as OMICmAge |
How quickly am I ageing at present? | Pace-of-ageing measurements such as DunedinPACE |
Which physiological systems require more attention? | System ages such as SYMPHONYAge |
What can be said about my telomere biology? | Direct or methylation-based telomere length measurement |
What are my everyday capacity and cardiorespiratory reserve like? | VO₂max, strength, balance and body composition |
In practice, the strongest assessment answers several of these questions together rather than just one.
What is OMICmAge, and what does it show?
OMICmAge is a next-generation epigenetic biomarker designed to connect overall biological ageing with multiple biological layers. Its development used information from electronic health records, clinical laboratory data, proteins and metabolites; these multiple biological signals were then translated into a score that can be read from DNA methylation.
In its development and validation study published in 2026, OMICmAge showed strong associations with chronic diseases and mortality risk across different cohorts. One of its main practical advantages is that, although it draws on multi-omic information, the measurement can be produced from DNA methylation in a single blood sample.
An OMICmAge result should not be read as “My body is definitely this age”. A more appropriate interpretation is to ask which ageing and health-risk profile in the reference population resembles the individual’s biological pattern. Used alongside conventional risk measurements, the result adds another layer to a personalised longevity plan.
What is DunedinPACE, and how does it measure the pace of ageing?
DunedinPACE estimates the pace of ageing rather than the level of biological age. The model was developed by tracking changes over 20 years, between ages 26–45, in the cardiovascular, metabolic, kidney, liver, lung, immune and other systems of people born in the same year. This long-term physiological change was then converted into a DNA methylation algorithm that can be calculated from a single blood sample.
The result is generally interpreted as a rate that approximately expresses “how many biological years of change occur in one calendar year”:
A value close to 1: A pace of ageing close to the reference level
A value above 1: A faster pattern of ageing relative to the reference
A value below 1: A slower pattern of ageing relative to the reference
These values are model-based comparisons, not exact biological time intervals. For example, a result of 1.10 does not mean that a person ages by exactly 1 year and 1 month every year.
One of DunedinPACE’s important strengths is its high test–retest reliability. It has also shown associations with disease burden, loss of function and mortality risk in different studies. These features make it valuable, particularly for monitoring the direction of change after a lifestyle or treatment plan. However, long-term intervention studies are still needed to show how much a change in the score brought about by an intervention changes healthspan.
What is SYMPHONYAge, and what do organ ages mean?
SYMPHONYAge uses the Systems Age approach described in the scientific literature to generate ageing patterns for 11 physiological systems from a single blood DNA methylation measurement. The areas assessed are:
Heart
Lung
Kidney
Liver
Brain
Immune system
Inflammation
Blood system
Musculoskeletal system
Hormonal system
Metabolic system
This approach is valuable because it makes the idea that organs do not all age at the same pace measurable. For example, while overall biological age may look relatively favourable, the metabolic or inflammatory system score may warrant more attention.
However, terms such as “heart age” and “brain age” must not be misunderstood. These are not diagnoses made by directly imaging the heart or brain. They are model outputs calculated from the relationship between methylation patterns measured in blood and the clinical biomarkers and health outcomes of the relevant system. A high system age therefore does not, on its own, mean that the organ is diseased; it is a signal that may suggest where a more detailed assessment should begin.
Does telomere length show biological age?
Telomeres are structures that protect the ends of chromosomes and generally tend to shorten as cells divide. For this reason, they have been studied for many years as an important biological indicator of ageing.
However, telomere length varies between individuals from birth and is influenced by genetics, cell distribution, the measurement method and lifetime exposures. A single telomere result cannot determine the biological age of the whole body.
Depending on the product, the value reported in an epigenetic test panel may be telomere length estimated from DNA methylation rather than a direct laboratory measurement. This approach can provide a valuable signal related to telomere biology, but it is not the same as measuring actual telomere length. A telomere result should therefore be viewed as a complementary part of the overall epigenetic profile, not used alone to make decisions about health or lifespan.
Are biological age tests genuinely reliable?
The short answer: Yes, when the right test is used to answer the right question in the right context; but the result is neither a definitive diagnosis nor destiny.
Reliability needs to be assessed at four separate levels:
1. Does repeating the measurement on the same sample give a similar result?
This is technical reproducibility. DNA methylation measurements can contain noise from sample preparation, chips, laboratories and data-processing steps. Some older epigenetic clocks have shown clinically important differences between repeated measurements of the same sample. Newer methods that use reliable CpG sites or reduce measurement noise can substantially reduce this problem. Technical reliability was specifically evaluated in the development studies of DunedinPACE and OMICmAge.
2. Does the test actually measure an ageing-related characteristic?
This is biological validity. Simply predicting a date of birth is not enough; the test’s connection to the physiological changes accompanying ageing also matters. The development of DunedinPACE from long-term changes in multiple organs, OMICmAge from clinical and multi-omic health data, and Systems Age from system-specific biomarkers is important in this respect.
3. Is the result associated with future disease and deterioration in health?
This is predictive validity. Large cohort studies have shown associations between newer epigenetic clocks and chronic disease, loss of function and mortality risk. A 2025 study comparing 14 epigenetic clocks with 174 incident disease outcomes in 18,859 people found that second- and third-generation clocks were stronger than first-generation clocks, but that there was no single “best clock” for every disease.
4. Does the test result improve health decisions?
This is clinical utility, the most challenging step in the evidence chain. A biological age test may reveal an otherwise unseen component of risk, help set priorities and monitor the direction of change over time. However, the extent to which the result improves particular decisions independently of standard risk calculations is not equally established for every test and every patient group.
Epigenetic clocks should therefore neither be dismissed nor treated as absolute. They are valuable biomarkers in longevity practice and perform best when added to a comprehensive clinical assessment.
To examine the evidence, personal need and follow-up plan when considering a test or programme, you can review the criteria for choosing a test and longevity programme.
Why do different biological age tests give different results?
Different results often reflect different questions being answered, rather than an error.
One clock may target chronological age, another mortality risk, and another the pace of ageing.
Some tests provide an overall score, while others focus on organs or systems.
Biological factors such as blood cell distribution, recent infection or inflammation may affect the result.
Sample collection, storage, the laboratory platform and the version of the algorithm may introduce technical differences.
The age, ancestry and health of the reference population may influence the calculation.
The age given by OMICmAge therefore cannot be directly compared with the pace given by DunedinPACE. They are not two versions of the same ruler, but complementary tools describing different dimensions of ageing.
How should a biological age test result be interpreted?
The following sequence can be used when interpreting a result:
First, establish what the test measures. Age, pace of ageing, a system score or a telomere signal?
Consider uncertainty as well as the size of the difference. A difference of a few years should not automatically be treated as a clinical problem.
Review conventional risks. Check blood pressure, ApoB or the lipid profile, glucose metabolism, and kidney and liver function.
Assess functional capacity. Include VO₂max, muscle strength, balance, mobility and body composition.
Examine modifiable areas such as sleep, nutrition, movement, stress, smoking and alcohol.
Seek clinical confirmation if a system score is high. For example, a high “heart age” is not a cardiovascular diagnosis; it may be a reason to undertake a more detailed conventional risk assessment.
In my clinical practice, I use these tests not to deliver a verdict on their own, but to understand a person’s ageing pattern in greater detail and personalise the follow-up plan. The most useful interpretation considers molecular results alongside examination findings and measurable health capacity.
Who might benefit from a biological age test?
A biological age test may be particularly useful for:
Adults who want to monitor their healthspan systematically
People seeking a more detailed view of long-term risk because of their family history or lifestyle
People whose standard tests are largely normal but who want a more comprehensive baseline assessment
People wishing to monitor the long-term effects of a nutrition, exercise, sleep or weight-management programme
People who want to understand which physiological systems may deserve priority, alongside an overall score
The test does not replace diagnostic investigation when symptoms or suspected disease are present. Problems such as chest pain, unexplained weight loss, anaemia or severe fatigue require conventional medical assessment first.
How often should a biological age test be repeated?
There is no single scientifically established repeat interval for everyone. Epigenetic markers are not designed to track weekly fluctuations; overly frequent testing may amplify technical and transient biological variability rather than reveal real biological change.
In practice, after a baseline measurement and a meaningful period of lifestyle change or treatment, reassessment at 6–12 months may be considered. However, this is not a universal rule; the interval varies with the person’s health and the goal being monitored.
Wherever possible, follow-up should use:
The same test and algorithm version,
The same sample type,
The same laboratory platform,
Similar sampling conditions.
Acute infections, newly developed serious illness or major medication changes should also be recorded when interpreting results. A consistent direction across several time points is more valuable than a small difference in one measurement.
Can biological age be reduced?
Biological age scores can change; some lifestyle and intervention studies have reported changes in epigenetic ageing indicators. However, because different scores measure different biological processes, an improvement in one clock may not appear in another.
More importantly, lowering a test result is not a treatment goal in itself. The real goals are to:
Improve blood pressure and metabolic risk,
Preserve muscle mass and strength,
Increase VO₂max and everyday mobility,
Improve sleep,
Reduce risks such as smoking and excessive alcohol,
Identify diseases early and manage them using evidence-based care.
Favourable changes in epigenetic indicators alongside these improvements are valuable, but they are not laboratory targets that can substitute for health benefits.
Can biological ageing be understood without a biological age test?
Even without calculating a single biological age number, strong insights into a person’s pace of ageing can be obtained. Waist circumference, blood pressure, glucose control, ApoB, kidney function, fitness, muscle strength, walking speed, sleep and cognitive performance are closely related to long-term health.
What an epigenetic test adds is a molecular and integrated layer to this assessment. The most appropriate approach is therefore not “conventional tests or a biological age test?” The right question is how the two sets of data can strengthen an individual health plan together.
Conclusion: biological age is a pattern that can be monitored, not a single number
Biological age tests, particularly newer epigenetic clocks, are among the most promising measurement tools in longevity medicine. OMICmAge makes visible the multiple biological signals associated with overall biological age and health risk; DunedinPACE the pace of ageing; and SYMPHONYAge the heterogeneity of ageing across physiological systems. Telomere length may add a complementary marker of cellular ageing to this picture.
The value of these results lies not in assigning a definitive “age label”, but in helping identify risks earlier, establish personal priorities and monitor the direction of change over time in the right clinical context. Biological age should be approached as a map of laboratory, functional, lifestyle and molecular information rather than the number produced by a single test.
Medical note: This content is for general information and does not replace individual diagnosis or treatment advice. A physician should assess test results alongside the person’s history, examination and other clinical findings.
References
Chen Q, Dwaraka VB, Carreras-Gallo N, et al. OMICmAge quantifies biological age by integrating multi-omics with electronic medical records. Nature Aging. 2026;6:722–737. doi:10.1038/s43587-026-01073-7
Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11. doi:10.7554/eLife.73420
Sehgal R, Markov Y, Qin C, et al. Systems Age: a single blood methylation test to quantify aging heterogeneity across 11 physiological systems. Nature Aging. 2025;5:1880–1896. doi:10.1038/s43587-025-00958-3
Moqri M, Herzog C, Poganik JR, et al. Validation of biomarkers of aging. Nature Medicine. 2024;30:360–372. doi:10.1038/s41591-023-02784-9
Mavrommatis C, Belsky DW, Ying K, et al. An unbiased comparison of 14 epigenetic clocks in relation to 174 incident disease outcomes. Nature Communications. 2025;16:11164. doi:10.1038/s41467-025-66106-y
Higgins-Chen AT, Thrush KL, Wang Y, et al. A computational solution for bolstering reliability of epigenetic clocks: implications for clinical trials and longitudinal tracking. Nature Aging. 2022;2:644–661. doi:10.1038/s43587-022-00248-2
Lu AT, Seeboth A, Tsai PC, et al. DNA methylation-based estimator of telomere length. Aging (Albany NY). 2019;11:5895–5923. doi:10.18632/aging.102173
Ferrucci L, Barzilai N, Belsky DW, Gladyshev VN. How to measure biological aging in humans. Nature Medicine. 2025;31:1057. doi:10.1038/s41591-025-03550-9
